Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Heartflow, Inc.HTFL · Entity 3993 | Chief Medical Officer | September 18, 2026 | September 21, 2026 |
| InspireMD, Inc.NSPR · Entity 7318 | Director | October 13, 2021 | October 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Heartflow, Inc.
Report date September 18, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,956 |
Ending reported balance
After 2026-09-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-18 · Exercise / conversion · Acquired 12,329 · Balance 98,788 F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. Row 2 · 2026-09-18 · Exercise / conversion · Acquired 850 · Balance 99,638 F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. Row 3 · 2026-09-18 · Sale · Disposed 19,682 · Balance 79,956 F2: Includes the sale of 6,503 shares of common stock held and the option exercise and sale of 13,179 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.33 · Expires 2030-02-28 | Direct | 31,456 |
Reported balance
After 2026-09-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-18 · Exercise / conversion · Disposed 12,329 · Balance 31,456 F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. F3: These stock options are fully exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2033-07-10 | Direct | 70,783 |
Reported balance
After 2026-09-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-18 · Exercise / conversion · Disposed 850 · Balance 70,783 F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. F4: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Campbell Rogers 2019 Irrevocable Trust | 22,615 |
Reported balance
Holding disclosure · report date 2026-09-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 22,615 |
| Common StockSEC Table I · non-derivative | IndirectBy CR Asset Protection Trust of 2023 | 46,159 |
Reported balance
Holding disclosure · report date 2026-09-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 46,159 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse's Trust | 26,012 |
Reported balance
Holding disclosure · report date 2026-09-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 26,012 |
| Common StockSEC Table I · non-derivative | IndirectBy The Campbell Rogers Revocable Trust | 50,754 |
Reported balance
Holding disclosure · report date 2026-09-18 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 50,754 |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
F2: Includes the sale of 6,503 shares of common stock held and the option exercise and sale of 13,179 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
F3: These stock options are fully exercisable.
F4: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.
InspireMD, Inc.
Report date October 13, 2021 · Filed October 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,960 |
Reported balance
After 2021-10-13 transaction · row 1
1 source rowRow 1 · 2021-10-13 · Grant · Acquired 17,248 · Balance 27,960 F1: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service. |
| Options to purchase common stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2031-10-13 | Direct | 5,749 |
Reported balance
After 2021-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-13 · Grant · Acquired 5,749 · Balance 5,749 F2: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service.
F2: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Corindus Vascular Robotics, Inc.
Report date October 29, 2019 · Filed October 31, 2019
Section 16 reporting ended · disclosed 2019-10-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 1
1 source rowRow 1 · 2019-10-29 · Disposition to issuer · Disposed 90,149 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: These shares represent 69,412 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2026-02-03 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-29 · Disposition to issuer · Disposed 98,522 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2026-09-26 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-29 · Disposition to issuer · Disposed 27,272 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-29 · Disposition to issuer · Disposed 17,857 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: These shares represent 69,412 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes.
F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant.
F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes.
F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2020 Filed Sep 2, 2020 16:55 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 158,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-017125 · ownership.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,635 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of August 31, 2021, August 31, 2022 and August 31, 2023, subject to the Reporting Person's continued service. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 17,857 | $2.60 Strike: $1.68 | $46,428.20 |
DisclosureSEC source: 0001387131-19-008133 · rogers-form4_102919.xml · derivative · entry 4 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,857 shares Expires 2027-06-21 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6 · derivative.exercise_date: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 27,272 | $3.18 Strike: $1.10 | $86,724.96 |
DisclosureSEC source: 0001387131-19-008133 · rogers-form4_102919.xml · derivative · entry 3 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,272 shares Expires 2026-09-26 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6 · derivative.exercise_date: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 98,522 | $2.25 Strike: $2.03 | $221,674.50 |
DisclosureSEC source: 0001387131-19-008133 · rogers-form4_102919.xml · derivative · entry 2 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,522 shares Expires 2026-02-03 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4 · derivative.exercise_date: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerCommon Stock | 90,149 | $4.28 | $385,837.72 |
DisclosureSEC source: 0001387131-19-008133 · rogers-form4_102919.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2 · shares: These shares represent 69,412 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs"). F3 · price: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes. Read SEC document |
| May 03, 2019 Filed May 7, 2019 18:36 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 27,649 | $2.17 | $59,998.33 |
DisclosureSEC source: 0001387131-19-003402 · rogers-form4_050319.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,149 F1 · shares: The common stock represents shares issuable upon vesting of restricted stock units (RSUs) granted as part of the director's 2019 annual equity award. The RSUs provide for vesting in quarterly installments on August 3, 2019, November 3, 2019, February 3, 2020 and May 3, 2020, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. (Corindus) through each such vesting date. F2 · balance_after: Includes 53,326 shares of common stock related to RSUs granted as part of the director's 2018 annual equity award which provided for vesting in quarterly installments on August 31, 2018, November 30, 2018, February 28, 2019 and May 31 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:30 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-001462 · ownership.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,011 Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 18:01 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 53,326 | $0.75 | $39,999.83 |
DisclosureSEC source: 0001387131-18-002521 · rogers-form4_053118.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 F1 · shares: The common stock represents shares issuable upon vesting of restricted stock units (RSUs) granted as part of the director's 2018 annual equity award. The RSUs provide for vesting in quarterly installments on August 31, 2018, November 30, 2018, February 28, 2019 and May 31, 2019, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. (Corindus) through each such vesting date. F2 · balance_after: Includes 9,174 shares of common stock related to RSUs granted as part of the director's 2017 annual equity award which provided for initial vesting of one-quarter of the granted units and subsequent quarterly vesting on December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus through each such vesting date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 20:17 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantRestricted Stock Units · Derivative | 9,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-17-005911 · rogers-form4_121517.xml · derivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,174 Underlying: Common Stock · 9,174 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock, par value $0.0001 per share, of Corindus Vascular Robotics, Inc. F2 · derivative.exercise_date: The restricted stock units were granted on December 15, 2017 as part of the director's annual equity award with vesting beginning as of June 22, 2017, the date of the 2017 Annual Meeting of Stockholders, The restricted stock units vest in four equal quarterly installments on September 22, 2017, December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Vested shares will be delivered to the reporting person within five days of each such vesting date. F2 · derivative.expiration_date: The restricted stock units were granted on December 15, 2017 as part of the director's annual equity award with vesting beginning as of June 22, 2017, the date of the 2017 Annual Meeting of Stockholders, The restricted stock units vest in four equal quarterly installments on September 22, 2017, December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Vested shares will be delivered to the reporting person within five days of each such vesting date. Read SEC document |
| December 15, 2017 Filed Mar 6, 2018 19:04 UTC Amendment | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 9,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-000947 · rogers-form4a_121517.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,174 F1 · balance_after: The common stock represents shares issuable upon vesting of restricted stock units granted as part of the director's annual equity award. The RSUs were initially vested with respect to one quarter of the granted units. The remaining quarterly installments will vest on December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:04 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantNon-qualified stock option (right to buy) · Derivative | 17,857 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001387131-17-003457 · rogers-form4_062217.xml · derivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,857 Underlying: Common Stock · 17,857 shares Expires 2027-06-21 F1 · derivative.exercise_date: The underlying shares vest over a period of three years with 33.33% vesting on the first anniversary of the issuance date and 8.334% vesting at the end of each calendar quarter thereafter. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 13:44 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001493152-16-015779 · form4.xml · derivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2026-12-07 F1 · derivative.exercise_date: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Rogers' continued service. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 17:41 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantNon-qualified stock option (right to buy) · Derivative | 27,272 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001387131-16-007141 · rogers-form4_092716.xml · derivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,272 Underlying: Common Stock · 27,272 shares Expires 2026-09-26 F1 · derivative.exercise_date: Vesting start date is June 23, 2016. The options vest over a period of three years with 33.33% vesting on the first anniversary of the vesting date and 8.334% vesting at the end of each calendar quarter thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.